Kenvue, Tylenol and FDA
Digest more
Kenvue stock is down 28% in 2025 amid controversy surrounding its Tylenol brand, which is linked to autism when used during ...
Starboard Value CEO Jeff Smith said that he is "thrilled to own" Kenvue (NYSE:KVUE) even though the stock is down ~30% year ...
A potential legal headache for consumer healthcare giant Kenvue ( KVUE 8.36%) was causing pain for investors on Thursday.
Explore Kenvue Inc. (NYSE:KVUE) trends, dividends, and market activity among consumer stocks in S&P 500 today.
I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.
(Reuters) -Kenvue has urged U.S. regulators to reject a request seeking autism warning label on its popular over-the-counter ...
If you’re eyeing Kenvue stock and asking yourself what to do next, you’re definitely not alone. There has been more than a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback